IHS Chemical Week


Pharma/fine chemicals roundup—21 June 2016

12:09 AM MDT | June 21, 2016 | By DEEPTI RAMESH

Hovione breaks ground on New Jersey expansion

Active pharmaceutical ingredients (APIs) producer Hovione (Loures, Portugal) says it held a groundbreaking ceremony on 8 June for the expansion of its East Windsor, NJ site, which would double its capacity to manufacture drug substance. The expansion, adding an additional 30,600 sq feet of space to the existing 24,000 sq feet facility, will include a new commercial spray dryer unit to complement the existing pilot unit which will be specifically designed to handle potent drug substances, Hovione says. The start-up of the operation is expected to take place in April 2017 for the drug substance and spray drying services, while the continuous drug product manufacturing is planned for the end of 2017.
“This investment is part of the company's strategy to increase its global development and commercial capacity which will meet the increasing demands of Hovione's customers in the API and spray drying services. It will also include the addition of a continuous drug product manufacturing capability to its offering through the partnership with Vertex Pharmaceuticals announced earlier this year,” says Kristine Senft, v.p./marketing and sales.  

AMRI selected as chemical biology consortium center to expand drug development

Albany Molecular Research Inc. (AMRI; Albany, NY) says that its Buffalo, NY site has been selected to participate as a dedicated chemical biology consortium center for the experimental therapeutics program, centered at the Frederick National Laboratory for Cancer Research. The Frederick National Lab, sponsored by the National Cancer Institute, is managing the expansion of the chemical biology consortium to 22 sites around the country with expertise in high-throughput screening, structural biology, medicinal chemistry, compound profiling, cancer cell biology, and animal models for oncology.
The chemical biology consortium is the discovery engine for the NCI experimental therapeutics program focused on advancing new cancer therapeutics against novel molecular and genetic cancer targets. AMRI's Buffalo facility, which is one of the only US-based fully integrated drug discovery centers with expertise with biology, chemistry and pharmacology, will provide a variety of drug discovery services to the consortium for a period of five years.

Air Products signs medical gases supply deal

Air Products has signed a deal with Vizient, a non-profit healthcare network, under which Air Products will supply medical gases to Vizient’s membership at negotiated prices. Members of Vizient’s network include community hospitals, pediatric facilities, academic medical centers, and a variety of healthcare providers. Terms of the deal, including financial details, have not been disclosed. Air Products has over 30 medical gas production facilities in the US, and has been in the medical oxygen business for several decades.

VANC Pharmaceuticals signs deal for exclusive in-license on a generic molecule and soon to be off patent molecule

VANC Pharmaceuticals (Vancouver), a pharmaceutical company focused on the Canadian generic drug and over-the-counter markets, says that it has entered into a definitive agreement for filing two abbreviated new drug submissions with exclusive marketing rights to Canada from an unnamed, manufacturer. The manufacturing company is vertically integrated and manufactures these and other products from active pharmaceutical ingredient to finished dosage forms. The manufacturer has US FDA and EU approved manufacturing facilities. One of these molecules ranks among the top three molecules in Canadian generics market in 2015, with the market size of about $150 million; the other product will become off patent in 2017.

Beyond IHS Chemical Week:

Indian drug advisory board backs proposed API import license fee hike
from in-PharmaTechnologist.com

A plan to charge drug firms more to import active pharmaceutical ingredients (APIs) into India has won the support of the Indian government’s drugs technical advisory board (DTAB). The fee increase, which was proposed by the Indian Ministry of Health and Family Welfare in December, was discussed at a DTAB meeting on 13 May where members agreed more funds are needed to support the Central Drugs Standard Control Organization. The DTAB highlighted the cost of an Indian API import license as an example, suggesting the current low fee is encouraging drug manufacturers to source actives from outside the country to the detriment of local producers.

Comments (1) for Pharma/fine chemicals roundup—21 June 2016
Good blog. I liked the content.
Posted by ChemAtoZ on Tuesday, June 21, 2016 @ 08:28 AM

RSS Follow us on Twitter Join us on LinkedIn Like us on Facebook Youtube channel
contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa